Latest news and press releases about Impact BioMedical Inc. (IBO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions.
Price
| Price | $0.50 |
| Market Cap | $54M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 4.56 |
| EV / EBITDA | -132.72 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 13.70% |
| Return on Invested Capital | 14.91% |
| Return on Assets | 4.71% |
| Gross Margin | -1111.43% |
| Operating Margin | -14562.86% |
| Net Margin | 2254.29% |
Related companies: ADIL · AIM · BCLI · CYCN · MLEC · NRSN · QNRX
Explore sector: Healthcare · Biotechnology
More sections of IBO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks